Home > Insider Trading > Filing (0001209191-14-071632)

Filing Details

Accession Number:: 0001209191-14-071632
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-11-26 19:19:47
Reporting Period:: 2014-11-26

Filing Date:: 2014-11-26
Accepted Time:: 2014-11-26 19:19:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1062822	Lexicon Pharmaceuticals Inc.	LXRX	Pharmaceutical Preparations (2834)	760474169

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053906	S.a. Group Artal	10-12 Avenue Pasteur Luxembourg N4 L-2310	Yes	No	Yes	No
1218180	S.c.a. International Artal	10-12 Avenue Pasteur Luxembourg N4 L-2310	Yes	No	Yes	No
1283968	S.a. Westend	10-12 Avenue Pasteur Luxembourg N4 L-2310	Yes	No	Yes	No
1340096	Invus Public Equities Advisors, Llc	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1340097	Invus Public Equities, L.p.	Clarendon House, 2 Church Street Hamilton Hm Ii D0	Yes	No	Yes	No
1404553	Invus Advisors, L.l.c.	750 Lexington Avenue, 30Th Floor New York NY 10022	Yes	No	Yes	No
1404570	Invus, L.p.	Clarendon House, 2 Church Street Hamilton Hm Ii D0	Yes	No	Yes	No
1460839	Pascal Minne	Place Ste. Gudule, 19 Bruxelles C9 B-1000	Yes	No	Yes	No
1460840	Westend Administratiekantoor Stichting	De Boelelaan 7, Amsterdam P7 NL-1083 HJ	Yes	No	Yes	No
1522131	S.a. Management International Artal	10-12 Avenue Pasteur Luxembourg N4 L-2310	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-11-26	149,253,731	$1.01	149,253,731	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	247,818,843	Indirect	See Footnotes
Common Stock	5,553,292	Indirect	See Footnotes

Footnotes

These securities are directly held by Artal International S.C.A.
These securities are directly held by Invus, L.P.
These securities are directly held by Invus Public Equities, L.P.
Invus Advisors, L.L.C. is the general partner of Invus, L.P., and Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P. Artal International S.C.A. is the managing member of each of Invus Advisors, L.L.C. and Invus Public Equities Advisors, LLC. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.